



TOS 2022 Webinar on Personalizing Obesity Management Continuing Medical Education Information for Learners

Credit for this course may not exceed 3.25 credits when both the live and enduring material activity format credits are combined.

Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of 3.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 201829502

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates enduring material for a maximum of 3.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 201829505

Important Dates for On-Demand Course (Enduring Material)

Date of Release: March 3, 2022

Date of Termination: March 1, 2025

Learning Objectives

1. Participants will be able to personalize their approach to obesity management by learning to obtain and consider their patient's individual history and narrative.
2. Participants will learn to consider psychological drivers and barriers in their patients with obesity.
3. Participants will be able to stage individual patients based on severity of their disease.
4. Participants will be able to better match treatments to individual patients based on their personal needs and expectations.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities¹ (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of an ineligible company. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker). In the case of this webinar, the chair was also the planner and speaker, so disclosures have been included in this document.

Panelists:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that "The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased."

Speaker Disclosures:

| | |
|--|---|
| Louis J. Aronne, MD, FACP, FTOS, DABOM | Consultant/Advisory Board Member relationship with Altimmune (Pharmaceuticals); Atria (Pharmaceuticals); Jazz Pharmaceuticals (Pharmaceuticals); Pfizer (Pharmaceuticals); Optum (Pharmaceuticals); Senda Biosciences (Pharmaceuticals); and Versanis (Pharmaceuticals). Consultant/Advisory Board Member, Research Funding, and Equity Interests relationship with Gelesis (Pharmaceuticals). Consultant/Advisory Board Member, Equity Interests, and Board of Directors relationship with Jamieson Wellness (Pharmaceuticals). Consultant/Advisory Board Member, Research Funding relationship with Janssen Pharmaceuticals (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); and Eli Lilly (Pharmaceuticals). Research Funding relationship with Astra Zeneca (Pharmaceuticals). Equity Interests and a Board of Directors' Member relationship Intellihealth (TOS Weight Management Telemedicine conflict - Not an ACCME conflict). |
| Denise Campbell-Scherer, MD, PhD, PhD, CCFP, FCFP | Consulting Fee relationship with Pfizer (Pharmaceuticals). Research grant to understand obesity in vulnerable people relationship with NOVAD (Novo Nordisk Pharmaceuticals & government consortium). |
| Robert F. Kushner, MD | No relevant financial relationships |
| Arya M. Sharma, MD, DSc (hon), FRCPC | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); and Johnson & Johnson (Medical Device). |
| Stephanie Sogg, PhD, FTOS | No relevant financial relationships |
| Sean Wharton, MD, FRCPC, PharmD | Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals); Bausch Health Canada (Pharmaceuticals); and Eli Lilly (Pharmaceuticals). |

Planner Disclosures:

| | |
|---|--|
| Arya M. Sharma, MD, DSc (hon), FRCPC | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); and Johnson & Johnson (Medical Device). |
|---|--|

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

1. Obesity in adults: a clinical practice guideline. <https://pubmed.ncbi.nlm.nih.gov/32753461/>

Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud'homme D, Salas XR, Rueda-Clausen C, Russell-Mayhew S, Shiao J, Sherifali D, Sievenpiper J, Sockalingam S, Taylor V, Toth E, Twells L, Tytus R, Walji S, Walker L, Wicklum S. *CMAJ*. 2020 Aug 4;192(31):E875-E891. doi: 10.1503/cmaj.191707.

2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

<https://pubmed.ncbi.nlm.nih.gov/27219496/>

Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. *Endocr Pract*. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24. PMID: 27219496

3. <https://www.guidelines.co.uk/public-health/nice-obesity-guideline/252547.article>

Obesity: identification, assessment and management

Published date: 27 November 2014 (amended February 2021) by The National Institute for Health and Care Excellence (NICE).

4. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society

<https://pubmed.ncbi.nlm.nih.gov/24222017/>

Michael D Jensen, Donna H Ryan, Caroline M Apovian, Jamy D Ard, Anthony G Comuzzie, Karen A Donato, Frank B Hu, Van S Hubbard, John M Jakicic, Robert F Kushner, Catherine M Loria, Barbara E Millen, Cathy A Nonas, F Xavier Pi-Sunyer, June Stevens, Victor J Stevens, Thomas A Wadden, Bruce M Wolfe, Susan Z Yanovski, Harmon S Jordan, Karima A Kendall, Linda J Lux, Roycelynn Mentor-Marcel, Laura C Morgan, Michael G Trisolini, Janusz Wnek, Jeffrey L Anderson, Jonathan L Halperin, Nancy M Albert, Biykem Bozkurt, Ralph G Brindis, Lesley H Curtis, David DeMets, Judith S Hochman, Richard J Kovacs, E Magnus Ohman, Susan J Pressler, Frank W Sellke, Win-Kuang Shen, Sidney C Smith Jr, Gordon F Tomaselli, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society

2014 Jun 24;129(25 Suppl 2):S139-40. DOI: 10.1161/01.cir.0000437739.71477.ee PMID: 24222017

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated February 24, 2022 v3.